Review



tgfβ receptor i  (Bioss)


Bioz Verified Symbol Bioss is a verified supplier
Bioz Manufacturer Symbol Bioss manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 92

    Structured Review

    Bioss tgfβ receptor i
    Tgfβ Receptor I, supplied by Bioss, used in various techniques. Bioz Stars score: 92/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tgfβ receptor i/product/Bioss
    Average 92 stars, based on 4 article reviews
    tgfβ receptor i - by Bioz Stars, 2026-06
    92/100 stars

    Images



    Similar Products

    92
    Bioss tgfβ receptor i
    Tgfβ Receptor I, supplied by Bioss, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tgfβ receptor i/product/Bioss
    Average 92 stars, based on 1 article reviews
    tgfβ receptor i - by Bioz Stars, 2026-06
    92/100 stars
      Buy from Supplier

    96
    MedChemExpress tgf β receptor i inhibitor sb431542
    Tgf β Receptor I Inhibitor Sb431542, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tgf β receptor i inhibitor sb431542/product/MedChemExpress
    Average 96 stars, based on 1 article reviews
    tgf β receptor i inhibitor sb431542 - by Bioz Stars, 2026-06
    96/100 stars
      Buy from Supplier

    95
    Selleck Chemicals tgf β type i ii receptor inhibitor
    ATRA alters the transcriptome of cashmere goat SHF-DPCs. (a) Principal component analysis (PCA) of transcriptome sequencing data from the control and ATRA-treated (10 −4 M, 24 h) groups. (b) Volcano plot showing differentially expressed genes (DEGs) between the control and ATRA-treated groups ( p < 0.05 and |log₂ fold change (FC)| > 1). (c) Relative mRNA expression of transforming growth factor-β2 <t>(TGF-</t> β 2) in the control and ATRA-treated groups (qRT-PCR). (d) Correlation between RNA sequencing and qRT-PCR data for selected DEGs based on log₂FC values; (e) Gene Ontology enrichment analysis of DEGs. (f) Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment bubble plot of DEGs. (g) Western blot analysis of TGF- β 2 expression in the control and ATRA-treated groups with corresponding quantitative analysis. (h) Western blot analysis of Smad2/3 phosphorylation levels in the control and ATRA-treated groups with corresponding quantitative analysis. Data are presented as the mean ± SD. * p < 0.05; ** p < 0.01; *** p < 0.001.
    Tgf β Type I Ii Receptor Inhibitor, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tgf β type i ii receptor inhibitor/product/Selleck Chemicals
    Average 95 stars, based on 1 article reviews
    tgf β type i ii receptor inhibitor - by Bioz Stars, 2026-06
    95/100 stars
      Buy from Supplier

    96
    MedChemExpress tgf β type i receptor inhibitor sb431542
    ATRA alters the transcriptome of cashmere goat SHF-DPCs. (a) Principal component analysis (PCA) of transcriptome sequencing data from the control and ATRA-treated (10 −4 M, 24 h) groups. (b) Volcano plot showing differentially expressed genes (DEGs) between the control and ATRA-treated groups ( p < 0.05 and |log₂ fold change (FC)| > 1). (c) Relative mRNA expression of transforming growth factor-β2 <t>(TGF-</t> β 2) in the control and ATRA-treated groups (qRT-PCR). (d) Correlation between RNA sequencing and qRT-PCR data for selected DEGs based on log₂FC values; (e) Gene Ontology enrichment analysis of DEGs. (f) Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment bubble plot of DEGs. (g) Western blot analysis of TGF- β 2 expression in the control and ATRA-treated groups with corresponding quantitative analysis. (h) Western blot analysis of Smad2/3 phosphorylation levels in the control and ATRA-treated groups with corresponding quantitative analysis. Data are presented as the mean ± SD. * p < 0.05; ** p < 0.01; *** p < 0.001.
    Tgf β Type I Receptor Inhibitor Sb431542, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tgf β type i receptor inhibitor sb431542/product/MedChemExpress
    Average 96 stars, based on 1 article reviews
    tgf β type i receptor inhibitor sb431542 - by Bioz Stars, 2026-06
    96/100 stars
      Buy from Supplier

    96
    Selleck Chemicals tgf β type i receptor inhibitor
    ATRA alters the transcriptome of cashmere goat SHF-DPCs. (a) Principal component analysis (PCA) of transcriptome sequencing data from the control and ATRA-treated (10 −4 M, 24 h) groups. (b) Volcano plot showing differentially expressed genes (DEGs) between the control and ATRA-treated groups ( p < 0.05 and |log₂ fold change (FC)| > 1). (c) Relative mRNA expression of transforming growth factor-β2 <t>(TGF-</t> β 2) in the control and ATRA-treated groups (qRT-PCR). (d) Correlation between RNA sequencing and qRT-PCR data for selected DEGs based on log₂FC values; (e) Gene Ontology enrichment analysis of DEGs. (f) Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment bubble plot of DEGs. (g) Western blot analysis of TGF- β 2 expression in the control and ATRA-treated groups with corresponding quantitative analysis. (h) Western blot analysis of Smad2/3 phosphorylation levels in the control and ATRA-treated groups with corresponding quantitative analysis. Data are presented as the mean ± SD. * p < 0.05; ** p < 0.01; *** p < 0.001.
    Tgf β Type I Receptor Inhibitor, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tgf β type i receptor inhibitor/product/Selleck Chemicals
    Average 96 stars, based on 1 article reviews
    tgf β type i receptor inhibitor - by Bioz Stars, 2026-06
    96/100 stars
      Buy from Supplier

    95
    MedChemExpress tgf β type i receptor alk5 kinase inhibitor
    ATRA alters the transcriptome of cashmere goat SHF-DPCs. (a) Principal component analysis (PCA) of transcriptome sequencing data from the control and ATRA-treated (10 −4 M, 24 h) groups. (b) Volcano plot showing differentially expressed genes (DEGs) between the control and ATRA-treated groups ( p < 0.05 and |log₂ fold change (FC)| > 1). (c) Relative mRNA expression of transforming growth factor-β2 <t>(TGF-</t> β 2) in the control and ATRA-treated groups (qRT-PCR). (d) Correlation between RNA sequencing and qRT-PCR data for selected DEGs based on log₂FC values; (e) Gene Ontology enrichment analysis of DEGs. (f) Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment bubble plot of DEGs. (g) Western blot analysis of TGF- β 2 expression in the control and ATRA-treated groups with corresponding quantitative analysis. (h) Western blot analysis of Smad2/3 phosphorylation levels in the control and ATRA-treated groups with corresponding quantitative analysis. Data are presented as the mean ± SD. * p < 0.05; ** p < 0.01; *** p < 0.001.
    Tgf β Type I Receptor Alk5 Kinase Inhibitor, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tgf β type i receptor alk5 kinase inhibitor/product/MedChemExpress
    Average 95 stars, based on 1 article reviews
    tgf β type i receptor alk5 kinase inhibitor - by Bioz Stars, 2026-06
    95/100 stars
      Buy from Supplier

    95
    MedChemExpress tgf β receptor i agonist sri 011381
    ATRA alters the transcriptome of cashmere goat SHF-DPCs. (a) Principal component analysis (PCA) of transcriptome sequencing data from the control and ATRA-treated (10 −4 M, 24 h) groups. (b) Volcano plot showing differentially expressed genes (DEGs) between the control and ATRA-treated groups ( p < 0.05 and |log₂ fold change (FC)| > 1). (c) Relative mRNA expression of transforming growth factor-β2 <t>(TGF-</t> β 2) in the control and ATRA-treated groups (qRT-PCR). (d) Correlation between RNA sequencing and qRT-PCR data for selected DEGs based on log₂FC values; (e) Gene Ontology enrichment analysis of DEGs. (f) Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment bubble plot of DEGs. (g) Western blot analysis of TGF- β 2 expression in the control and ATRA-treated groups with corresponding quantitative analysis. (h) Western blot analysis of Smad2/3 phosphorylation levels in the control and ATRA-treated groups with corresponding quantitative analysis. Data are presented as the mean ± SD. * p < 0.05; ** p < 0.01; *** p < 0.001.
    Tgf β Receptor I Agonist Sri 011381, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tgf β receptor i agonist sri 011381/product/MedChemExpress
    Average 95 stars, based on 1 article reviews
    tgf β receptor i agonist sri 011381 - by Bioz Stars, 2026-06
    95/100 stars
      Buy from Supplier

    96
    Selleck Chemicals tgf β type i receptor
    ATRA alters the transcriptome of cashmere goat SHF-DPCs. (a) Principal component analysis (PCA) of transcriptome sequencing data from the control and ATRA-treated (10 −4 M, 24 h) groups. (b) Volcano plot showing differentially expressed genes (DEGs) between the control and ATRA-treated groups ( p < 0.05 and |log₂ fold change (FC)| > 1). (c) Relative mRNA expression of transforming growth factor-β2 <t>(TGF-</t> β 2) in the control and ATRA-treated groups (qRT-PCR). (d) Correlation between RNA sequencing and qRT-PCR data for selected DEGs based on log₂FC values; (e) Gene Ontology enrichment analysis of DEGs. (f) Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment bubble plot of DEGs. (g) Western blot analysis of TGF- β 2 expression in the control and ATRA-treated groups with corresponding quantitative analysis. (h) Western blot analysis of Smad2/3 phosphorylation levels in the control and ATRA-treated groups with corresponding quantitative analysis. Data are presented as the mean ± SD. * p < 0.05; ** p < 0.01; *** p < 0.001.
    Tgf β Type I Receptor, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tgf β type i receptor/product/Selleck Chemicals
    Average 96 stars, based on 1 article reviews
    tgf β type i receptor - by Bioz Stars, 2026-06
    96/100 stars
      Buy from Supplier

    93
    Addgene inc tβri
    ATRA alters the transcriptome of cashmere goat SHF-DPCs. (a) Principal component analysis (PCA) of transcriptome sequencing data from the control and ATRA-treated (10 −4 M, 24 h) groups. (b) Volcano plot showing differentially expressed genes (DEGs) between the control and ATRA-treated groups ( p < 0.05 and |log₂ fold change (FC)| > 1). (c) Relative mRNA expression of transforming growth factor-β2 <t>(TGF-</t> β 2) in the control and ATRA-treated groups (qRT-PCR). (d) Correlation between RNA sequencing and qRT-PCR data for selected DEGs based on log₂FC values; (e) Gene Ontology enrichment analysis of DEGs. (f) Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment bubble plot of DEGs. (g) Western blot analysis of TGF- β 2 expression in the control and ATRA-treated groups with corresponding quantitative analysis. (h) Western blot analysis of Smad2/3 phosphorylation levels in the control and ATRA-treated groups with corresponding quantitative analysis. Data are presented as the mean ± SD. * p < 0.05; ** p < 0.01; *** p < 0.001.
    Tβri, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tβri/product/Addgene inc
    Average 93 stars, based on 1 article reviews
    tβri - by Bioz Stars, 2026-06
    93/100 stars
      Buy from Supplier

    Image Search Results


    ATRA alters the transcriptome of cashmere goat SHF-DPCs. (a) Principal component analysis (PCA) of transcriptome sequencing data from the control and ATRA-treated (10 −4 M, 24 h) groups. (b) Volcano plot showing differentially expressed genes (DEGs) between the control and ATRA-treated groups ( p < 0.05 and |log₂ fold change (FC)| > 1). (c) Relative mRNA expression of transforming growth factor-β2 (TGF- β 2) in the control and ATRA-treated groups (qRT-PCR). (d) Correlation between RNA sequencing and qRT-PCR data for selected DEGs based on log₂FC values; (e) Gene Ontology enrichment analysis of DEGs. (f) Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment bubble plot of DEGs. (g) Western blot analysis of TGF- β 2 expression in the control and ATRA-treated groups with corresponding quantitative analysis. (h) Western blot analysis of Smad2/3 phosphorylation levels in the control and ATRA-treated groups with corresponding quantitative analysis. Data are presented as the mean ± SD. * p < 0.05; ** p < 0.01; *** p < 0.001.

    Journal: Frontiers in Veterinary Science

    Article Title: All-trans retinoic acid modulates proliferation and apoptosis of secondary hair follicle–dermal papilla cells in cashmere goats via the TGF- β 2/Smad2/3 pathway

    doi: 10.3389/fvets.2026.1765302

    Figure Lengend Snippet: ATRA alters the transcriptome of cashmere goat SHF-DPCs. (a) Principal component analysis (PCA) of transcriptome sequencing data from the control and ATRA-treated (10 −4 M, 24 h) groups. (b) Volcano plot showing differentially expressed genes (DEGs) between the control and ATRA-treated groups ( p < 0.05 and |log₂ fold change (FC)| > 1). (c) Relative mRNA expression of transforming growth factor-β2 (TGF- β 2) in the control and ATRA-treated groups (qRT-PCR). (d) Correlation between RNA sequencing and qRT-PCR data for selected DEGs based on log₂FC values; (e) Gene Ontology enrichment analysis of DEGs. (f) Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment bubble plot of DEGs. (g) Western blot analysis of TGF- β 2 expression in the control and ATRA-treated groups with corresponding quantitative analysis. (h) Western blot analysis of Smad2/3 phosphorylation levels in the control and ATRA-treated groups with corresponding quantitative analysis. Data are presented as the mean ± SD. * p < 0.05; ** p < 0.01; *** p < 0.001.

    Article Snippet: SHF-DPCs were seeded into 96-well plates at a density of 5 × 10 3 cells/well in 100 μL of medium and cultured at 37 °C with 5% CO2 for 24 h. After removal of the complete culture medium, cells were washed with PBS and treated with ATRA (HY-14649, MedChemExpress, Monmouth Junction, NJ, United States) at different concentrations (10 −8 , 10 −7 , 10 −6 , 10 −5 , 10 −4 , 10 −3 M) for 24, 48 or 72 h. For mechanistic validation experiments, SHF-DPCs were treated with ATRA (10 −4 M) and/or LY2109761 (2 μM), a TGF- β type I/II receptor inhibitor (S2704; Selleck Chemicals, Houston, TX, United States), for 24 h. ATRA and LY2109761 were prepared in complete culture medium, and the control group received an equal volume of culture medium.

    Techniques: Sequencing, Control, Expressing, Quantitative RT-PCR, RNA Sequencing, Western Blot, Phospho-proteomics

    ATRA regulates proliferation and apoptosis in cashmere goat SHF-DPCs via the TGF- β 2/Smad2/3 pathway. (a) Representative images of EdU staining of SHF-DPCs treated with ATRA (10 −4 M) LY2109761 (2 μM), or ATRA + LY2109761 (scale bar = 200 μm). (b) Representative images of TUNEL staining of SHF-DPCs treated with ATRA, LY2109761, or ATRA + LY2109761 (scale bar = 200 μm). (c) CCK-8 assay to assess cell viability of SHF-DPCs treated with ATRA, LY2109761, or ATRA + LY2109761. (d) Western blot analysis of Bcl-2 and Bax expression in SHF-DPCs treated with ATRA, LY2109761, or ATRA + LY2109761 with corresponding quantitative analysis. (e) Western blot analysis of Smad2/3 phosphorylation levels in SHF-DPCs treated with ATRA, LY2109761, or ATRA + LY2109761 with corresponding quantitative analysis. Data are presented as the mean ± SD. * p < 0.05; ** p < 0.01; *** p < 0.001; ns, not significant.

    Journal: Frontiers in Veterinary Science

    Article Title: All-trans retinoic acid modulates proliferation and apoptosis of secondary hair follicle–dermal papilla cells in cashmere goats via the TGF- β 2/Smad2/3 pathway

    doi: 10.3389/fvets.2026.1765302

    Figure Lengend Snippet: ATRA regulates proliferation and apoptosis in cashmere goat SHF-DPCs via the TGF- β 2/Smad2/3 pathway. (a) Representative images of EdU staining of SHF-DPCs treated with ATRA (10 −4 M) LY2109761 (2 μM), or ATRA + LY2109761 (scale bar = 200 μm). (b) Representative images of TUNEL staining of SHF-DPCs treated with ATRA, LY2109761, or ATRA + LY2109761 (scale bar = 200 μm). (c) CCK-8 assay to assess cell viability of SHF-DPCs treated with ATRA, LY2109761, or ATRA + LY2109761. (d) Western blot analysis of Bcl-2 and Bax expression in SHF-DPCs treated with ATRA, LY2109761, or ATRA + LY2109761 with corresponding quantitative analysis. (e) Western blot analysis of Smad2/3 phosphorylation levels in SHF-DPCs treated with ATRA, LY2109761, or ATRA + LY2109761 with corresponding quantitative analysis. Data are presented as the mean ± SD. * p < 0.05; ** p < 0.01; *** p < 0.001; ns, not significant.

    Article Snippet: SHF-DPCs were seeded into 96-well plates at a density of 5 × 10 3 cells/well in 100 μL of medium and cultured at 37 °C with 5% CO2 for 24 h. After removal of the complete culture medium, cells were washed with PBS and treated with ATRA (HY-14649, MedChemExpress, Monmouth Junction, NJ, United States) at different concentrations (10 −8 , 10 −7 , 10 −6 , 10 −5 , 10 −4 , 10 −3 M) for 24, 48 or 72 h. For mechanistic validation experiments, SHF-DPCs were treated with ATRA (10 −4 M) and/or LY2109761 (2 μM), a TGF- β type I/II receptor inhibitor (S2704; Selleck Chemicals, Houston, TX, United States), for 24 h. ATRA and LY2109761 were prepared in complete culture medium, and the control group received an equal volume of culture medium.

    Techniques: Staining, TUNEL Assay, CCK-8 Assay, Western Blot, Expressing, Phospho-proteomics